Condensed Consolidated Statements of Operations and Comprehensive Loss (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended		6 Months Ended
	Jun. 30, 2012	Jun. 30, 2011	Jun. 30, 2012	Jun. 30, 2011
Revenue	$ 25,509	$ 19,175	$ 50,028	$ 37,723
Cost of goods sold	6,277	4,150	11,703	8,523
Gross profit	19,232	15,025	38,325	29,200
Operating expenses:
Research and development	4,995	5,178	8,810	9,184
Clinical and regulatory affairs	1,862	898	3,264	1,815
Marketing and sales	13,083	10,402	26,218	20,900
General and administrative	4,457	3,324	8,872	6,903
Contract termination and business acquisition expenses	422	400	422	400
Total operating expenses	24,819	20,202	47,586	39,202
Loss from operations	(5,587)	(5,177)	(9,261)	(10,002)
Other income (expense):
Interest income	4	6	7	16
Interest expense	(13)	(2)	(20)	(9)
Gain on sale of equipment	0	141	0	141
Other income (expense), net	16	(34)	15	(7)
Change in fair value of contingent consideration related to acquisition	(1,240)	(8,600)	(13,690)	(8,600)
Total other expense	(1,233)	(8,489)	(13,688)	(8,459)
Net loss before income tax expense	(6,820)	(13,666)	(22,949)	(18,461)
Income tax benefit (expense)	124	0	(450)	0
Net loss	(6,696)	(13,666)	(23,399)	(18,461)
Basic and diluted net loss per share	$ (0.11)	$ (0.24)	$ (0.40)	$ (0.33)
Shares used in computing basic and diluted net loss per share	58,700	56,217	58,160	56,062
Comprehensive loss:
Foreign currency translation adjustment	133	0	108	0
Comprehensive loss	$ (6,563)	$ (13,666)	$ (23,291)	$ (18,461)